The #1 Paranormal News Site
The body of Ken Shefveland had become so swollen up with cancer when all treatment had failed, and then doctors took a gamble and started him on a radical approach. Doctors took away some of his immune cells and then engineered them into assassins of cancer and then let them go into his bloodstream.
One of the newest and hottest trends in cancer care is immune therapy. The next frontier is the creation of living drugs that are able to grow inside the body of a human being and they turn into an army that seeks and then destroys the tumors.
Shefveland said that when he looks into the mirror, he can almost see cancer melting away. When he went to the doctors one month later at the Fred Hutchinson Cancer Research Centre, they were unable to find signs of cancer inside of his body. Shefveland said that today he is in full remission and that was wonderful.
The experimental therapy marks a brand new way to treat cancer providing they are able to make the therapy works safely. Early stages of the studies have now stirred hope and single infusions of supercharged immune cells will be able to help a remarkable number of patients that are suffering from lymphoma and intractable leukemia.
Dr. David Maloney said that it showed the unbelievable power of the immune system of the body. The medical director of Fred Hutch for cellular immunotherapy who had been the doctor of Shefveland treated his patient with a type called CAR-T cells.
Dr. Stanley Riddell, the immunotherapy scientific director, said that there were still plenty to learn. He went on to say that the T cells are going to play the role of immune system soldiers but said that cancer is often difficult to spot and is able to stop an immune attack.
He went on to say that the popular immunotherapy drugs which are called checkpoint inhibitors release a brake close that the T cells that are nearby can strike. The cellular immunotherapy approach is going to have more potency, and it gives cancer patients T cells that are stronger to start with.
The CAR-T cell therapy is only available in studies at the major cancer centers, but the first cell therapies for just a few blood cancers may be on the market much later on this year.
The Food and Drug Administration has been evaluating a version that was developed by the University of Pennsylvania and which has been licensed to Novartis, while another was created by the National Cancer Institute and has been licensed to Kite Pharma.
Scientists are now looking to tackle a much tougher step, and this is what Haining has called the acid test. This is to ensure that the T cells target cancer that is more common, including solid tumors such as lung, brain and breast cancer. While there is a great deal of excitement, they are still faced with challenges that are formidable.
Scientists are still trying to work out why the living cancer drugs seem to work for some people but not on other people. Doctors have to learn how they are going to manage what might be potentially life-threatening side effects due to an overstimulated immune system.
They are also worried about a small number of deaths from swelling to the brain; this is a complication that is unexplained and which was the cause of Juno Therapeutics stopping development of CAR-T that they had been working on.
When it is made from scratch taking the blood from the person with cancer, it costs many hundreds of thousands of dollars, and it is one of the most customized of therapies known.